Souhaitez-vous accéder aux communiqués récents ?

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Biotalys announces that it will publish its annual report and financial results for the full year of 2025 on Wednesday, 29 April 2026 at 07:00 CEST.

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members –...

LONDON, 24 Mar. 2026 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information...

Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results...

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients...

ABC Arbitrage 2025 Results¹: €25.1 m ROE 2025: 14.8% | Per share distribution 2025: €0.3 4 The Board of Directors of ABC arbitrage, presided by the Chairman Dominique Ceolin, met on March 19, 2026...

ABC arbitrage Résultat consolidé 20251 : 25,1 M€ ROE 2025 : 14,8 % | Distribution par action 2025 : 0,34 € Le conseil d’administration de la société ABC arbitrage s’est réuni le 19 mars 2026,...

Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 24, 2026 dsm-firmenich, innovators in...